Core Viewpoint - Popular, Inc. is a leading regional financial institution with a strong presence in Puerto Rico and expanding operations in select U.S. and Caribbean markets, leveraging a diversified product offering and extensive branch network to drive customer engagement and deposit growth [1] Group 1: Company Overview - Popular serves individuals, small and medium-sized businesses, and institutional clients across Puerto Rico, the U.S. mainland, and the British Virgin Islands [2] - The company generates revenue primarily through net interest income from lending activities and fee-based services such as insurance, leasing, and brokerage operations [2] Group 2: Recent Transaction - Alejandro M Sanchez, Director of Popular, reported the sale of 1,451 shares of common stock in an open-market transaction on February 26, 2026, with shares priced around $140.85, amid a one-year total return of 45.95% [3][5][6] - The sale accounted for 29.83% of Sanchez's direct holdings, reducing his ownership from 4,865 to 3,414 shares, marking his first reported open-market sale of common stock [4][6] Group 3: Financial Performance - Popular had a strong year with a GAAP net income of approximately $833.1 million in 2025, up from $614.2 million in 2024, representing a 27% increase in adjusted net income [6] - Loans and deposits grew while credit quality improved, and the bank repurchased over $500 million worth of shares, authorizing an additional $500 million repurchase program and raising its quarterly dividend to $0.75 per share, yielding around 2.2% [7] Group 4: Market Outlook - Analysts have raised their average price target for Popular stock to $170 from $161, as a more normalized yield curve improves profitability outlook for regional banks, with the stock price up 7.8% year to date as of March 24 [8]

Company Overview - Abivax is a France-based biotech company that experienced a share price increase of over 1,740% last year due to progress with its leading drug candidate, obefazimod [1] - The current market capitalization of Abivax is approximately 8.74 billion euros ($10.15 billion) [5] Drug Candidate: Obefazimod - Obefazimod is being developed to treat ulcerative colitis (UC), a market currently dominated by major pharmaceutical companies [2] - Unlike existing UC therapies that suppress the immune system, obefazimod aims to control symptoms without compromising immune function [3] - In a phase 3 study, obefazimod demonstrated statistically significant remission in patients with moderate to severe UC, with 47.3% of participants having inadequate responses to prior therapies [3] Market Potential - The therapy has the potential to exceed blockbuster status at its peak, indicating strong market prospects [4] - Eli Lilly is reportedly preparing a bid of 15 billion euros ($17.42 billion) to acquire Abivax, representing a 72% premium over its current market cap [5][6] Competitive Landscape - Eli Lilly, a leader in the weight loss market, is looking to expand its portfolio and could enhance its competitiveness in the immunology market through the acquisition of obefazimod [6] - There is a possibility that other pharmaceutical companies may also consider acquiring Abivax due to the promising prospects of obefazimod [6] Investment Considerations - The potential acquisition by Eli Lilly could lead to a significant increase in Abivax's stock price, while the absence of an acquisition may result in a loss of value [8] - Despite the promising clinical data for obefazimod, potential clinical or regulatory setbacks could pose risks to the stock [7]

Core Insights - The transaction indicates a significant insider purchase by Srinivas Akkaraju, Director of Alumis, acquiring 588,235 shares for approximately $10.0 million, reflecting a strong belief in the company's future performance [5][6]. Company Overview - Alumis is a clinical-stage biotechnology company focused on developing therapies for autoimmune and neuroinflammatory diseases, leveraging advanced TYK2 inhibitor technology to address unmet medical needs [7]. Transaction Details - The shares were purchased at $17.00 each, which is below recent market prices, suggesting a favorable entry point for the insider [2][6]. - This acquisition is one of the largest recorded for Akkaraju, increasing his cumulative indirect holdings by nearly 47% in a single transaction [4][5]. Market Performance - Alumis' stock has appreciated significantly, with a 206.29% increase over the past year and over 400% in the last three months, indicating strong market confidence [5][8]. - The company recently reported successful phase 3 trial results for envudeucitinib, showing that 65% of patients achieved a 90% or better improvement in psoriasis severity scores [9]. Competitive Landscape - Alumis' psoriasis treatment candidate appears to be more effective than Amgen's Otezla, which had 33% of patients achieving a 75% improvement in similar trials [10].